Search

Your search keyword '"Dekkers, Coco"' showing total 23 results
Start Over Author "Dekkers, Coco"
23 results on '"Dekkers, Coco"'

1. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry

Author

Zhang, Junfen, Boesjes, Celeste M., Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L.E., Spekhorst, Lotte S., Haeck, Inge, van der Gang, Lian F., Dekkers, Coco C., van der Rijst, Lisa P., Oosting, Albert J., van Lumig, Paula, van Lynden-van Nes, Anneke M.T., Tupker, Ron A., Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R.H., Christoffers, Wianda A., Stewart, Shiarra M., Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S., and Schuttelaar, Marie-Louise A.

Published
2024
Full Text
View/download PDF

2. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis.

Author

Boesjes, Celeste M., Kamphuis, Esmé, de Graaf, Marlies, Spekhorst, Lotte S., Haeck, Inge, van der Gang, Lian F., Loman, Laura, Zuithoff, Nicolaas P. A., Dekkers, Coco, van der Rijst, Lisa P., Romeijn, Geertruida L. E., Oosting, Albert J., Gostynksi, Antoni, van Lynden-van Nes, Anneke M. T., Tupker, Ron A., van Tuyll van Serooskerken, Anne-Moon, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R. H., and Christoffers, Wianda A.

Published
2024
Full Text
View/download PDF

3. Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Author

Unit Opleiding Dermatologie, Infection & Immunity, MS Dermatologie/Allergologie, Zhang, Junfen, Boesjes, Celeste M, Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L E, Spekhorst, Lotte S, Haeck, Inge, van der Gang, Lian F, Dekkers, Coco C, van der Rijst, Lisa P, Oosting, Albert J, van Lumig, Paula, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R H, Christoffers, Wianda A, Stewart, Shiarra M, Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, Schuttelaar, Marie-Louise A, Unit Opleiding Dermatologie, Infection & Immunity, MS Dermatologie/Allergologie, Zhang, Junfen, Boesjes, Celeste M, Loman, Laura, Kamphuis, Esmé, Romeijn, Margreet L E, Spekhorst, Lotte S, Haeck, Inge, van der Gang, Lian F, Dekkers, Coco C, van der Rijst, Lisa P, Oosting, Albert J, van Lumig, Paula, van Lynden-van Nes, Anneke M T, Tupker, Ron A, Nijssen, Annieke, Flinterman, Annebeth, Politiek, Klaziena, Touwslager, Wouter R H, Christoffers, Wianda A, Stewart, Shiarra M, Kamsteeg, Marijke, de Graaf, Marlies, de Bruin-Weller, Marjolein S, and Schuttelaar, Marie-Louise A

Published
2024

5. Type 2 Immune‐Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients.

Author

Dekkers, Coco, Smits, Hidde, Stölzl, Dora, Spekhorst, Lotte, Knol, Edward, Wijk, Femke, Harder, Inken, Werfel, Thomas, Schmitt, Jochen, Kleinheinz, Andreas, Abraham, Susanne, Thijs, Judith, Weidinger, Stephan, Bruin‐Weller, Marjolein, Bakker, Daphne, and Drylewicz, Julia

Subjects
*HEPATOCYTE growth factor, *MEDICAL personnel, *ATOPIC dermatitis, *BLOOD proteins, *PRINCIPAL components analysis
Abstract

The study in Clinical & Experimental Allergy found that the Type 2 immune-dominant endotype is not linked to increased responsiveness to dupilumab treatment in adult atopic dermatitis patients. The research did not identify any biological evidence to exclude atopic dermatitis patients from considering dupilumab treatment based on their endotype. The study suggests that all atopic dermatitis patients should be considered for dupilumab treatment regardless of their Type 2 endotype. [Extracted from the article]

Published
2024
Full Text
View/download PDF

10. IgE levels in patients with atopic dermatitis steadily decrease during treatment with dupilumab regardless of dose interval

Author

Infection & Immunity, MS Dermatologie/Allergologie, CTI Van Wijk, Unit Opleiding Dermatologie, Child Health, Dekkers, Coco, van der Wal, M Marlot, van den Noort, Leonie, Bakker, Daphne S, de Bruin-Weller, Marjolein, van Wijk, Femke, Infection & Immunity, MS Dermatologie/Allergologie, CTI Van Wijk, Unit Opleiding Dermatologie, Child Health, Dekkers, Coco, van der Wal, M Marlot, van den Noort, Leonie, Bakker, Daphne S, de Bruin-Weller, Marjolein, and van Wijk, Femke

Published
2023

11. Limited excretion of dupilumab into breastmilk: A case report

Author

MS Dermatologie/Allergologie, Infection & Immunity, Apotheek KF TDM, Apotheek Klinische Farmacie, Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Dekkers, Coco, El Amrani, Mohsin, van Luin, Matthijs, Bakker, Daphne, Plusjé, Leon, van Wijk, Femke, de Bruin-Weller, Marjolein, MS Dermatologie/Allergologie, Infection & Immunity, Apotheek KF TDM, Apotheek Klinische Farmacie, Unit Opleiding Dermatologie, CTI Van Wijk, Child Health, Dekkers, Coco, El Amrani, Mohsin, van Luin, Matthijs, Bakker, Daphne, Plusjé, Leon, van Wijk, Femke, and de Bruin-Weller, Marjolein

Published
2023

12. Switching from dupilumab to tralokinumab in atopic dermatitis patients with ocular surface disease: Preliminary case series

Author

MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Achten, Roselie, Dekkers, Coco, Bakker, Daphne, van Luijk, Chantal, de Graaf, Marlies, van Wijk, Femke, de Boer, Joke, de Bruin-Weller, Marjolein, Thijs, Judith, MS Dermatologie/Allergologie, Infection & Immunity, Unit Opleiding Dermatologie, MS Oogheelkunde, Other research (not in main researchprogram), CTI Van Wijk, Child Health, Achten, Roselie, Dekkers, Coco, Bakker, Daphne, van Luijk, Chantal, de Graaf, Marlies, van Wijk, Femke, de Boer, Joke, de Bruin-Weller, Marjolein, and Thijs, Judith

Published
2023

13. Biological Tipping Point in Patients with Atopic Dermatitis Treated with Different Dosing Intervals of Dupilumab

Author

MS Dermatologie/Allergologie, Infection & Immunity, CTI Van Wijk, Apotheek KF TDM, Apotheek Klinische Farmacie, Unit Opleiding Dermatologie, Child Health, Dekkers, Coco, van der Wal, M Marlot, El Amrani, Mohsin, van Luin, Matthijs, Bakker, Daphne S, de Bruin-Weller, Marjolein, van Wijk, Femke, MS Dermatologie/Allergologie, Infection & Immunity, CTI Van Wijk, Apotheek KF TDM, Apotheek Klinische Farmacie, Unit Opleiding Dermatologie, Child Health, Dekkers, Coco, van der Wal, M Marlot, El Amrani, Mohsin, van Luin, Matthijs, Bakker, Daphne S, de Bruin-Weller, Marjolein, and van Wijk, Femke

Published
2023

14. The pleiotropic role of interleukin-13 in the pathogenesis of atopic dermatitis.

Author

Dekkers, Coco and Bruin-Weller, Marjolein de

Subjects
*SKIN physiology, *ATOPIC dermatitis, *NONPROFIT sector, *INFLAMMATION, *INTERLEUKIN-13
Abstract

This article, published in the British Journal of Dermatology, discusses the role of interleukin-13 (IL-13) in the development of atopic dermatitis (AD). The study suggests that IL-13 is a key driver of AD, impacting skin barrier function and the local immune response. The researchers examined the effects of tralokinumab, a monoclonal antibody that targets IL-13, on skin barrier function and biology in a cohort of 16 AD patients. They found that tralokinumab improved skin physiology, epidermal pathology, and microbial dysbiosis, indicating the importance of IL-13 in AD pathogenesis. The study also highlights the complexity of AD and the need for further research on the role of IL-13 in skin barrier recovery. [Extracted from the article]

Published
2024
Full Text
View/download PDF

19. The diagnostic accuracy and prognostic value of OCT for the evaluation of the visual function in children with a brain tumour: A systematic review

Author

Oogheelkunde Onderzoek, Cancer, MS Oogheelkunde, Infection & Immunity, MS Dermatologie/Allergologie, Zorglijn Achtersegment, MS KNO, Brain, Nuijts, Myrthe A., Imhof, Saskia M., Veldhuis, Nienke, Dekkers, Coco C., Schouten-Van Meeteren, Antoinette Y.N., Stegeman, Inge, Oogheelkunde Onderzoek, Cancer, MS Oogheelkunde, Infection & Immunity, MS Dermatologie/Allergologie, Zorglijn Achtersegment, MS KNO, Brain, Nuijts, Myrthe A., Imhof, Saskia M., Veldhuis, Nienke, Dekkers, Coco C., Schouten-Van Meeteren, Antoinette Y.N., and Stegeman, Inge

Published
2021

20. Safety and effectiveness of omalizumab for the treatment of chronic urticaria in pediatric patients

Author

MS Dermatologie/Allergologie, Infection & Immunity, Dekkers, Coco, Alizadeh Aghdam, Mehran, Graaf, Marlies de, Knulst, André C, Meijer, Yolanda, van den Reek, Juul M P A, Stadermann, Marike B, Röckmann, Heike, MS Dermatologie/Allergologie, Infection & Immunity, Dekkers, Coco, Alizadeh Aghdam, Mehran, Graaf, Marlies de, Knulst, André C, Meijer, Yolanda, van den Reek, Juul M P A, Stadermann, Marike B, and Röckmann, Heike

Published
2021

23. Overcoming Obstacles in Lipid-lowering Therapy in Patients with HIV - A Systematic Review of Current Evidence.

Author

Dekkers, Coco C., Hoepelman, Andy I. M., Arends, Joop E., and Westerink, Jan

Abstract

Cardiovascular risk management in human immunodeficiency virus (HIV)-infected individuals is gaining increased attention due to the rising incidence and prevalence of cardiovascular disease in this population. Despite the availability of efficacious treatment strategies, implementation of guideline advocated preventive therapy, such as lipid-lowering therapy with statins, is hampered by perceived, expected, and real side effects as well as by expected interactions with combination antiretroviral therapy. These obstacles to optimal treatment have resulted in a large gap between the number of patients in whom lipidlowering therapy is indicated and those actually taking lipid-lowering medication. In the past few years, research has shown that the majority of patient-reported side effects is not causally related to statin therapy but is attributable to the nocebo effect. Furthermore, excessive caution due to expected drug interactions between statins and antiretroviral therapy is often unnecessary, especially with novel classes of antiretroviral therapy. The main aim of this review is to discuss the causes and consequences of this lipid-lowering treatment gap in HIV-infected patients together with a practical guide on how to overcome these obstacles. In addition, new treatment options on the optimal cardiovascular management focusing primarily on novel classes of antiretroviral therapy and lipid-lowering medication will be discussed. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results